Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR -1.01%65 Debt-to-EBITDA is 1.81 as of Mar. 2026, which is 66% below its 10-year median of 5.29. GuruFocus rates NSE:STAR with a GF Score™ of 65/100 and a GF Value™ of ₹759.78 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 689 Drug Manufacturers companies, Strides Pharma Science ranks worse than 50.07% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Strides Pharma Science's Debt-to-EBITDA or its related term are showing as below:
NSE:STAR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.05 Med: 5.29 Max: 17.35
Current: 1.68
During the past 13 years, the highest Debt-to-EBITDA Ratio of Strides Pharma Science was 17.35. The lowest was -11.05. And the median was 5.29.
NSE:STAR's Debt-to-EBITDA is ranked worse than 50.07% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs NSE:STAR: 1.68
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Strides Pharma Science Debt-to-EBITDA Related Terms
Strides Pharma Science Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Strides Pharma Science's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Strides Pharma Science (NSE:STAR) has a Debt-to-EBITDA of 1.81 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strides Pharma Science. This is 66% below median its historical median of 5.29. According to the industry distribution chart, Strides Pharma Science ranks #345 out of 689 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Strides Pharma Science's Debt-to-EBITDA too high?
Strides Pharma Science's current Debt-to-EBITDA of 1.81 is 66% below median its 10-year median of 5.29. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Strides Pharma Science's value of 1.81 is 7.7% above this industry median. Based on the distribution chart, Strides Pharma Science ranks #345 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #345 out of 689 companies for Debt-to-EBITDA. This places Strides Pharma Science in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Strides Pharma Science's value of 1.81 is 7.7% above this benchmark. While the company's 10-year median is 5.29 vs. the industry median of 1.68, Strides Pharma Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Debt-to-EBITDA of 1.81 is 7.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strides Pharma Science. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Debt-to-EBITDA is 1.81, which is 66% below median its own 10-year median of 5.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹759.78, compared to a current price of ₹1,040.70 — trading 37% above its estimated fair value. The current Debt-to-EBITDA is 1.81, which is 66% below median its 10-year median of 5.29 and 7.7% above the Drug Manufacturers industry median of 1.68. Strides Pharma Science's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Debt-to-EBITDA is 1.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,040.70 is trading 37% above its estimated GF Value™ of ₹759.78.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Debt-to-EBITDA: 1.81 (66% below median its 10-year median of 5.29)
GF Value™: ₹759.78 vs. price of ₹1,040.70 (37% above fair value)
Industry Position: 7.7% above the Drug Manufacturers median (#345 of 689)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
65GF Score
Get the complete analysis for NSE:STAR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
